The new treatment for basal cell nevus syndrome, also called Gorlin syndrome, springs from an unlikely location: Idaho’s mountain pastures.
Richard D. Carvajal, MD, has been named director of the Experimental Therapeutics/Phase I program and melanoma service in medical oncology at NewYork-Presbyterian/Columbia University Medical Center, effective Nov. 1, 2014.
Precision medicine for lung cancer is now allowing some patients to live for years with advanced disease, and better therapies are in the works.
Daniel Seidman, author of “Smoke-Free in 30 Days,” will participate in a blogtalkradio show Nov. 17 in advance of this year’s Great American Smokeout on Nov. 20.
A CUMC study found that the use of generic aromatase inhibitors, which cost considerably less than their brand-name counterparts, increased treatment adherence by 50 percent.
Using an innovative algorithm, CUMC researchers have found that loss of a gene called KLHL9 is the driving force behind the most aggressive form of glioblastoma, the most common form of brain cancer.